Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies
Overview
Authors
Affiliations
Objectives: This study sought to determine the incidence and prevalence of atrial fibrillation (AF) in transthyretin cardiac amyloidosis (ATTR-CA); to study the factors associated with the development of AF in this population; to study the prognostic implications of AF and maintenance of normal sinus rhythm (NSR) in patients with ATTR-CA; and to determine the impact of ATTR-CA stage on AF prevalence, outcomes, and efficacy of rhythm control strategies.
Background: AF is common in patients with ATTR-CA. The aim of this study was to determine the predictors, prevalence, and outcomes of AF in patients with ATTR-CA in addition to the efficacy of rhythm control strategies.
Methods: This was a retrospective cohort study of 382 patients with ATTR-CA diagnosed at our institution between January 2004 and January 2018. Means testing, and univariable and multivariable models were used.
Results: AF occurred in 265 (69%) patients. Factors associated with the development of AF included older age, advanced ATTR-CA stage, and higher left atrial volume index. Antiarrhythmic therapy (AAT) was used in 35% of patients with AF; cardioversion was performed in 45%, and 5% underwent AF ablation. Rhythm control strategies were substantially more effective when performed earlier in the disease course. During a mean follow-up of 35 months, no difference in mortality between patients with AF and those without AF was observed (65% vs. 49%; p = 0.76). On Cox proportional hazards analyses, maintenance of normal sinus rhythm and tafamidis use were associated with improved survival, whereas advanced ATTR-CA stage and higher New York Heart Association functional class were associated with increased mortality.
Conclusions: With advancing ATTR-CA stage, AF became more prevalent, occurring in 69% of our entire study cohort. Rhythm control strategies including AAT, direct-current cardioversion, and AF ablation were substantially more effective when performed earlier during the disease course.
Guenancia C, Lequeux B, Amara W, Buiciuc O, Damy T, Defaye P JACC Adv. 2025; 4(3):101604.
PMID: 39954342 PMC: 11872529. DOI: 10.1016/j.jacadv.2025.101604.
Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review.
Delgado D, Dabbous F, Shivappa N, Mazhar F, Wittbrodt E, Shridharmurthy D Orphanet J Rare Dis. 2025; 20(1):29.
PMID: 39819351 PMC: 11740649. DOI: 10.1186/s13023-025-03547-0.
His108Arg Transthyretin Amyloidosis-Shedding Light on a Distinctively Malignant Variant.
Binder C, Schmid L, Kronberger C, Poledniczek M, Rettl R, Schlein J J Clin Med. 2025; 13(24.
PMID: 39768780 PMC: 11728263. DOI: 10.3390/jcm13247857.
Teresi L, Trimarchi G, Liotta P, Restelli D, Licordari R, Carciotto G J Clin Med. 2024; 13(18).
PMID: 39337075 PMC: 11432666. DOI: 10.3390/jcm13185588.
Dobner S, Zarro S, Wieser F, Kassar M, Alaour B, Wiedemann S J Clin Med. 2024; 13(17).
PMID: 39274501 PMC: 11396384. DOI: 10.3390/jcm13175291.